Medicinal cannabis manufacturer Bioxyne has received its first order of GMP-manufactured psilocybin capsules for investigational use in treatment-resistant depression.
The order will see Bioxyne subsidiary Breathe Life Sciences (BLS) supply 250 doses to authorised prescribers in Queensland and Western Australia to treat approximately 60 patients over the next 12 months.
The capsules will also be used for exploratory research into other mental health conditions including anxiety disorders, substance use disorder and PTSD.
Bioxyne chief executive Sam Watson said BLS was “translating its psychedelic manufacturing capabilities into early commercial results and positive patient outcomes”.
“For Bioxyne, these initial supply agreements reflect disciplined execution at the outset of a multi-billion dollar opportunity with the potential to meaningfully improve quality of life for millions of people,” he said.
Article by Cannabiz – https://www.cannabiz.com.au/news-in-brief-bioxyne-receives-first-psilocybin-order/